Stock listing
Cboe Canada:METX ME Therapeutics Holdings, Inc. Stock
Canadian listing (Cboe Canada) of ME Therapeutics Holdings, Inc. · home listing CSE:METX
Follow ME Therapeutics Holdings, Inc. into a list and get an email when it puts out news.
Home listing price · CSE:METX
$1.05 CAD 0.00 (0.0%)
Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:METX
- Day range
- $1.05 – $1.05 CADNov 19, 2026
- Market cap
- $31.91M CADAt the close on Nov 19, 2026 · price × 30.39M shares outstanding
- 52-week range
- $0.79 – $4.10 CADLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $2,554 CADMedian day 0 shares · 38 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:METX · Home | $1.05 CAD | 0.00 (0.0%) | — | $1.05 | $1.05 | $1.05 | $1.05 | Close on Nov 19, 2026 |
| Frankfurt:Q9T | €0.752 EUR | +0.006 (+0.8%) | — | €0.752 | €0.752 | €0.752 | €0.746 | Close on Nov 17, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · CSE:METX · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | +0.05 | +5.0% | $1.05 | $1.05 | $1.05 | 38,000 | |
| $1.00 | -0.05 | -4.8% | $0.95 | $1.00 | $0.95 | 41,550 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 0 | |
| $1.05 | 0.00 | 0.0% | $1.05 | $1.05 | $1.05 | 1,000 | |
| $1.05 | -0.05 | -4.5% | $1.10 | $1.10 | $1.05 | 10,628 | |
| $1.10 | 0.00 | 0.0% | $1.10 | $1.10 | $1.10 | 0 | |
| $1.10 | 0.00 | 0.0% | $1.10 | $1.10 | $1.10 | 0 | |
| $1.10 | 0.00 | 0.0% | $1.10 | $1.10 | $1.10 | 0 | |
| $1.10 | +0.04 | +3.8% | $1.10 | $1.10 | $1.10 | 200 | |
| $1.06 | 0.00 | 0.0% | $1.06 | $1.06 | $1.06 | 0 | |
| $1.06 | 0.00 | 0.0% | $1.06 | $1.06 | $1.06 | 0 | |
| $1.06 | 0.00 | 0.0% | $1.06 | $1.06 | $1.06 | 0 | |
| $1.06 | 0.00 | 0.0% | $1.06 | $1.06 | $1.06 | 0 | |
| $1.06 | 0.00 | 0.0% | $1.06 | $1.06 | $1.06 | 0 | |
| $1.06 | +0.01 | +1.0% | $1.06 | $1.06 | $1.06 | 100 | |
| $1.05 | +0.10 | +10.5% | $1.05 | $1.05 | $1.05 | 600 | |
| $0.95 | -0.85 | -47.2% | $0.96 | $0.96 | $0.95 | 2,500 | |
| $1.80 | 0.00 | 0.0% | $1.80 | $1.80 | $1.80 | 0 | |
| $1.80 | +0.20 | +12.5% | $1.80 | $1.80 | $1.80 | 200 | |
| $1.60 | -1.20 | -42.9% | $1.60 | $1.61 | $1.51 | 4,020 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | +0.80 | +40.0% | $2.80 | $2.80 | $2.80 | 500 | |
| $2.00 | -0.80 | -28.6% | $1.75 | $2.00 | $1.60 | 1,300 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | +0.80 | +40.0% | $2.80 | $2.80 | $2.80 | 300 | |
| $2.00 | 0.00 | 0.0% | $2.00 | $2.00 | $2.00 | 0 | |
| $2.00 | +0.25 | +14.3% | $1.85 | $2.00 | $1.85 | 200 | |
| $1.75 | 0.00 | 0.0% | $1.75 | $1.75 | $1.75 | 0 | |
| $1.75 | 0.00 | 0.0% | $1.76 | $1.76 | $1.75 | 3,008 | |
| $1.75 | -2.35 | -57.3% | $2.80 | $2.80 | $1.75 | 2,200 | |
| $4.10 | 0.00 | 0.0% | $4.10 | $4.10 | $4.10 | 0 | |
| $4.10 | +1.10 | +36.7% | $3.73 | $4.10 | $3.73 | 3,276 | |
| $3.00 | +1.40 | +87.5% | $1.60 | $3.00 | $1.60 | 2,900 | |
| $1.60 | -0.65 | -28.9% | $1.60 | $1.60 | $1.60 | 1,100 | |
| $2.25 | 0.00 | 0.0% | $2.25 | $2.25 | $2.25 | 0 | |
| $2.25 | 0.00 | 0.0% | $2.25 | $2.25 | $2.25 | 0 | |
| $2.25 | -0.25 | -10.0% | $2.25 | $2.25 | $2.25 | 1,200 | |
| $2.50 | 0.00 | 0.0% | $2.50 | $2.50 | $2.50 | 0 | |
| $2.50 | 0.00 | 0.0% | $2.50 | $2.50 | $2.50 | 0 | |
| $2.50 | 0.00 | 0.0% | $2.50 | $2.50 | $2.50 | 0 | |
| $2.50 | 0.00 | 0.0% | $2.50 | $2.50 | $2.50 | 0 | |
| $2.50 | 0.00 | 0.0% | $2.50 | $2.50 | $2.50 | 900 | |
| $2.50 | +0.35 | +16.3% | $2.50 | $2.50 | $2.50 | 101 | |
| $2.15 | +0.65 | +43.3% | $2.00 | $2.15 | $2.00 | 475 | |
| $1.50 | -0.40 | -21.1% | $1.50 | $1.50 | $1.50 | 9,400 | |
| $1.90 | 0.00 | 0.0% | $1.90 | $1.90 | $1.90 | 0 | |
| $1.90 | 0.00 | 0.0% | $1.90 | $1.90 | $1.90 | 0 | |
| $1.90 | -0.90 | -32.1% | $3.04 | $3.25 | $1.90 | 1,500 | |
| $2.80 | 0.00 | 0.0% | $2.80 | $2.80 | $2.80 | 0 | |
| $2.80 | +1.04 | +59.1% | $2.80 | $2.80 | $2.80 | 100 | |
| $1.76 | +0.01 | +0.6% | $1.76 | $1.76 | $1.76 | 300 |
- Ticker
- Cboe Canada:METX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Cboe Canada
- Currency
- CAD
What changed lately
Latest news release · Nov 9, 2026
ME Therapeutics Engages Orbiton Financial for Investor Awareness
Latest deck · June 2026
Investor Presentation (June 2026)
Investor deck · 19 slides
Latest news
ME Therapeutics Engages Orbiton Financial for Investor Awareness
Nov 9, 2026
Closed $1.05 (0.0%) on Nov 9, 2026
ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset
Oct 9, 2026
Closed $2.80 (0.0%) on Oct 13, 2026
ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs
Sep 8, 2026
Closed $2.50 (0.0%) on Sep 8, 2026
ME Therapeutics Closes Over-Subscribed Private Placement
Jul 17, 2026
Closed $2.94 (+47.7%) on Jul 17, 2026
ME Therapeutics Announces Private Placement
Jun 3, 2026
Closed $1.99 (0.0%) on Jun 3, 2026
ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver
May 7, 2026
Closed $2.95 (0.0%) on May 7, 2026
ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs
Apr 29, 2026
Closed $2.50 (0.0%) on Apr 29, 2026
ME Therapeutics Scientific and Corporate Update
Jan 30, 2026
Closed $2.20 (0.0%) on Jan 30, 2026
ME Therapeutics Attending JP Morgan Healthcare Conference
Jan 6, 2026
Closed $3.80 (+5.8%) on Jan 7, 2026
ME Therapeutics Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 28 in all · newest Nov 9, 2026 · oldest 2023
- Decks
- 4 decks · latest June 2026
Where ME Therapeutics Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:METX · Home listing | CSE | Canada | CAD |
| Cboe Canada:METX · This page | Cboe Canada | Canada | CAD |
| OTC:METXF | OTC | United States | USD |
| Frankfurt:Q9T | Frankfurt | Germany | EUR |
Valuation
Price/book 49.5× against a median of 1.1×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Mar 31, 2026 · price Nov 19, 2026
- Enterprise value
- $31.37M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 49.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 0.52
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ME Therapeutics Holdings, Inc. · CSE:METX | US$22.25M | US$21.88M | n/a | n/a | n/a | 49.5× | n/a | 0.0× | 0.52 |
| Incannex Healthcare Inc. · NASDAQ:IXHL | US$23.33M | −US$44.85M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.98 |
| Actinogen Medical Limited · ASX:ACW | US$23.08M | US$15.17M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| CervoMed Inc. · NASDAQ:CRVO | US$22.09M | US$2.49M | n/a | 285× | n/a | 1.3× | n/a | 0.0× | 1.97 |
| Sona Nanotech, Inc. · CSE:SONA | US$21.84M | US$22.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Mendus AB · OMXSTO:IMMU | US$21.76M | US$17.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | n/a |
| Metagenomi Therapeutics, Inc. · NASDAQ:MGX | US$21.36M | −US$44.10M | n/a | −6.2× | n/a | 0.2× | n/a | 0.4× | 1.65 |
| NanoGroup SA · GPW:NNG | US$21.32M | US$18.78M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Cel-Sci Corporation · AMEX:CVM | US$21.28M | US$14.76M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.13 |
| Median of the others | US$21.96M | US$14.96M | 140× | 1.1× | 0.0× | 0.98 |
Team and board
Officers
| Officer | Role |
|---|---|
| Salim Dhanji | Chief Executive Officer & Founder |
| Quinn Martin | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| John Priatel | Director |
| Karim Nanji | Director |
| Kenneth Harder | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2026) | Investor deck | 19 slides | June 2026 |
| Investor Presentation (October 2025) | Investor deck | 16 slides | Oct 16, 2025 |
| Investor Presentation (March 2025) | Investor deck | 24 slides | March 2025 |
| Investor Presentation (December 2023) | Investor deck | 25 slides | December 2023 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$576,501 raised · C$1.7 a unit · Warrants at C$2 for 36 months Buyers: John Priatel (294,118 Units for an investment of $500,000.60) Insiders: Director John Priatel was issued 294,118 Units for an investment of $500,000.60; related party transaction under MI 61-101 Use of proceeds: R&D, evaluating strategic transactions, pursuing a U.S. listing, marketing, investor relations, working capital and general corporate purposes | Jul 17, 2026 | US$411,375 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Research and development | 412.1K | 312.0K | 27.1K | 54.7K |
| Selling, general and administrative | 780.1K | 1.06M | 950.2K | 97.3K |
| Operating income | -1.22M | -1.37M | -6.55M | -162.8K |
| Depreciation and amortization | 83.3K | 40 | 50 | 60 |
| EBITDA | -1.13M | -1.37M | -6.55M | -162.7K |
| Interest expense | 12.7K | 0 | 7.46K | 10.8K |
| Income before tax | -1.19M | -1.29M | -6.52M | -145.8K |
| Net income | -1.19M | -1.29M | -6.52M | -145.8K |
| Earnings per share, basic | -0.04 | -0.05 | -0.28 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 1.35M | 1.50M | 647.1K | 77.4K |
| Short-term investments | 57.5K | 0 | ||
| Current assets | 1.50M | 1.54M | 671.7K | 102.2K |
| Property, plant and equipment | 160 | 200 | 250 | |
| Total assets | 1.76M | 1.54M | 671.9K | 102.5K |
| Accounts payable | 155.2K | 46.1K | 106.7K | 34.2K |
| Current liabilities | 245.4K | 62.9K | 148.5K | 173.9K |
| Long-term debt | 0 | 60.0K | ||
| Total liabilities | 256.3K | 62.9K | 148.5K | 233.9K |
| Shareholders' equity | 1.50M | 1.48M | 523.4K | -131.5K |
| Shares outstanding | 29.6M | 25.2M | 23.6M | 23.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -862.3K | -657.9K | -303.2K | -135.7K |
| Capital spending | -216.2K | 0 | 0 | 0 |
| Free cash flow | -1.08M | -657.9K | -303.2K | -135.7K |
| Cash from investing | 0 | 757.4K | ||
| Cash from financing | 995.5K | 1.51M | 115.5K | 140.0K |
| Share buybacks | 1.55M | 0 | ||
| Change in cash | -151.3K | 849.6K | 569.8K | 4.32K |
Cap table
Built by 6ix from ME Therapeutics Holdings, Inc.’s releases · as of Jul 17, 2026
- Common shares
- 30,388,612
- Fully diluted
- 32,438,612
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 30,388,612 | Jul 17, 2026 |
| Options and RSUs | 2,050,000 |
Warrants and options
| Lot |
|---|
| Warrants · C$2.00 · expire about Jul 2029 |
| Stock options · C$1.05 · expire Nov 5, 2028 |
| Stock options · C$1.99 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Jul 17, 2026 | 30,388,612 |
| Mar 31, 2026 | 30,049,494 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Priatel | Director · Since at least Jul 17, 2026 |
| Karim Nanji | Director · Since at least Nov 5, 2026 |
| Kenneth Harder | Director · Since at least Nov 5, 2026 |
| Quinn Martin | Chief Financial Officer · Since at least Nov 5, 2026 |
| Salim Dhanji | Chief Executive Officer & Founder · Since at least Mar 3, 2025 |
Log in to ask 6ix AI your own questions about ME Therapeutics Holdings, Inc.